Global Blood Therapeutics Announces Participation at the Stifel 2017 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) GBT today announced that it will present at the Stifel 2017 Healthcare Conference in New York City on Tuesday, November 14, 2017 at 2:00 p.m. Eastern Time.

The presentation will be webcast live and available for replay from GBT's website at www.globalbloodtx.com in the Investors section.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit: www.globalbloodtx.com and follow the company on Twitter: @GBT_news

   

Contact Information:

Myesha Lacy (investors)

GBT

650-351-4730

investor@globalbloodtx.com

Julie Normart (media)

Pure Communications

415-946-1087

media@globalbloodtx.com

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPress ReleasesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!